Disc Medicine, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Disc Medicine, Inc. (IRON) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-07-30
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.28M, a 435.10% decline year-over-year.
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $4.55M, a 37.12% decline year-over-year.
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $1.38M.
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$371.00K.
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $8.92M.
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$1.57M, a 234.73% decline from fiscal 2023.
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.17M.
- Disc Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$352.00K, a 125.77% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.26M 10-Q · filed 2026-07-30 | $3.65M derived: sum of 3 quarters · filed 2026-07-30 | $3.27M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $4.55M 10-Q · filed 2026-05-05 | $5.93M derived: sum of 2 quarters · filed 2026-05-05 | $5.56M derived: sum of 3 quarters · filed 2026-05-05 | $6.24M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.01M derived: sum of 2 quarters · filed 2026-02-26 | $1.69M derived: sum of 3 quarters · filed 2026-07-30 | $8.92M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$371.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $310.00K derived: sum of 2 quarters · filed 2026-07-30 | $7.54M 10-Q · filed 2025-11-06 | $5.46M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $681.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $7.91M 10-Q · filed 2026-07-30 | $5.83M derived: sum of 3 quarters · filed 2026-07-30 | $4.72M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $7.23M 10-Q · filed 2026-05-05 | $5.15M derived: sum of 2 quarters · filed 2026-05-05 | $4.04M derived: sum of 3 quarters · filed 2026-05-05 | $1.55M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.19M derived: sum of 2 quarters · filed 2026-02-26 | -$5.68M derived: sum of 3 quarters · filed 2026-02-26 | -$1.57M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.60M derived: sum of 2 quarters · filed 2025-11-06 | $509.00K 10-Q · filed 2025-11-06 | $2.02M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.62M 10-Q · filed 2025-08-07 | $3.12M derived: sum of 3 quarters · filed 2026-02-26 | $2.91M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $4.11M 10-Q · filed 2025-05-07 | $5.62M derived: sum of 2 quarters · filed 2026-02-26 | $5.41M derived: sum of 3 quarters · filed 2026-02-26 | $4.37M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.29M derived: sum of 2 quarters · filed 2026-02-26 | $258.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.17M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | -$213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.25M derived: sum of 2 quarters · filed 2024-11-12 | -$341.00K 10-Q · filed 2024-11-12 | -$2.38M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$128.00K 10-Q · filed 2024-08-08 | -$2.17M derived: sum of 3 quarters · filed 2024-08-08 | -$2.34M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $908.00K 10-Q · filed 2024-05-09 | -$1.13M derived: sum of 2 quarters · filed 2024-05-09 | -$1.30M derived: sum of 3 quarters · filed 2024-05-09 | $3.75M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$2.21M derived: sum of 2 quarters · filed 2024-03-21 | $2.84M derived: sum of 3 quarters · filed 2024-03-21 | -$352.00K 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | -$171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.88M derived: sum of 2 quarters · filed 2023-11-09 | $1.69M 10-Q · filed 2023-11-09 | -$323.00K 10-Q · filed 2022-11-10 | -$1.04M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.86M 10-Q · filed 2023-08-11 | $1.22M 10-Q · filed 2022-08-11 | -$872.00K derived: sum of 3 quarters · filed 2023-08-11 | -$46.00K derived: sum of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | -$3.19M 10-Q · filed 2023-05-15 | $1.43M 10-Q · filed 2022-05-06 | -$5.93M derived: sum of 2 quarters · filed 2023-05-15 | -$5.10M derived: sum of 3 quarters · filed 2023-05-15 | -$4.89M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$1.91M derived: sum of 2 quarters · filed 2023-03-31 | -$1.69M derived: sum of 3 quarters · filed 2023-03-31 | $1.37M 10-K · filed 2023-03-31 | $2.54M 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $826.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.04M derived: sum of 2 quarters · filed 2022-11-10 | $4.10M 10-Q · filed 2022-11-10 | $3.67M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.27M 10-Q · filed 2022-08-11 | $2.84M derived: sum of 3 quarters · filed 2022-08-11 | $2.21M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $3.06M 10-Q · filed 2022-05-06 | $2.63M derived: sum of 2 quarters · filed 2022-05-06 | $2.00M derived: sum of 3 quarters · filed 2022-05-06 | $1.50M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | -$428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$1.06M derived: sum of 2 quarters · filed 2022-03-10 | -$1.56M derived: sum of 3 quarters · filed 2022-03-10 | -$1.68M 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | -$633.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$1.13M derived: sum of 2 quarters · filed 2021-11-15 | -$1.25M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | -$499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$616.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$117.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |